再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REGN 再生元制药公司

盘前交易 07-14 06:58:08 EDT

567.74

+7.98

+1.43%

盘前566.50

-1.24-0.22%

06:08 EDT

最高568.46	最低551.48	成交量84.46万
今开558.39	昨收559.76	日振幅3.03%
总市值612.96亿	流通市值567.12亿	总股本1.08亿
成交额4.77亿	换手率0.85%	流通股本9,989万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":567.74,"timestamp":1752264000000,"preClose":559.76,"halted":0,"volume":844604,"hourTrading":{"tag":"盘前","latestPrice":566.5,"preClose":567.74,"latestTime":"06:08 EDT","volume":14,"amount":7939.999199999999,"timestamp":1752487683169},"delay":0,"floatShares":99889916,"shares":107965497,"eps":39.427654,"marketStatus":"盘前交易","change":7.98,"latestTime":"07-14 06:58:08 EDT","open":558.39,"high":568.46,"low":551.48,"amount":476527350.4684,"amplitude":0.030334,"askPrice":581,"askSize":1,"bidPrice":541,"bidSize":5,"shortable":3,"etf":0,"ttmEps":39.427654,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752499800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":567.74,"dividendRate":0.0031,"preHourTrading":{"tag":"盘前","latestPrice":566.5,"preClose":567.74,"latestTime":"06:08 EDT","volume":14,"amount":7939.999199999999,"timestamp":1752487683169},"postHourTrading":{"tag":"盘后","latestPrice":567.75,"preClose":567.74,"latestTime":"19:59 EDT","volume":43478,"amount":24684237.32,"timestamp":1752278380281},"volumeRatio":1.0730833367618138,"impliedVol":0.4304,"impliedVolPercentile":0.7952},"requestUrl":"/m/hq/s/REGN/wiki","defaultTab":"wiki","newsList":[{"id":"2550992664","title":"Accelerated FDA Approval of Lynozyfic May Change the Case for Investing in Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2550992664","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550992664?lang=zh_cn&edition=full","pubTime":"2025-07-12 14:02","pubTimestamp":1752300139,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals recently received accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed or refractory multiple myeloma who have undergone at least four prior therapies, addressing a significant medical need in oncology.\nThis regulatory milestone not only bolsters Regeneron's late-stage cancer portfolio but also overcomes earlier manufacturing challenges that delayed approval, enhancing the company's outlook in a competitive...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"FDA加速批准Lynozyfic可能会改变投资再生元(REGN)的理由","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/accelerated-fda-approval-of-lynozyfic-may-change-the-case-fo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2362540622.SGD","LU0289739699.SGD","LU0109394709.USD","BK4588","LU0114720955.EUR","LU0823434583.USD","LU0058720904.USD","LU0882574055.USD","LU2362541513.USD","REGN","LU1917777945.USD","LU2023250504.SGD","LU0320765992.SGD","LU0053666078.USD","LU0823434740.USD","BK4139","LU2362541273.HKD","LU0889565916.HKD","LU2089984988.USD","BK4585","LU2106854487.HKD","LU0823416689.USD","LU2468319806.SGD","LU1974910355.USD","LU2237438978.USD"],"gpt_icon":0},{"id":"2550312999","title":"再生元制药公司7月11日成交额为4.77亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550312999","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550312999?lang=zh_cn&edition=full","pubTime":"2025-07-12 13:14","pubTimestamp":1752297289,"startTime":"0","endTime":"0","summary":"美东时间2025年7月11日，再生元制药公司成交额为4.77亿美元，成交额较昨日增加2.92%，当日成交量为84.46万股。再生元制药公司于2025年7月11日涨1.43%，报567.74美元，该股过去5个交易日涨3.72%，年初至今跌20.07%，过去60日跌0.43%。该公司有多种已上市产品，包括获批用于湿性年龄相关性黄斑变性和其他眼病的低剂量Eylea 和 Eylea HD、免疫学领域的达必妥；用于降低低密度脂蛋白胆固醇的波立达；肿瘤学领域的Libtayo；以及类风湿性关节炎领域的Kevzara。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712131456a4460f7d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2089984988.USD","LU0053666078.USD","LU2362541513.USD","REGN","LU2362540622.SGD","LU0058720904.USD","LU0889565916.HKD","BK4139","LU0823416689.USD","LU0320765992.SGD","LU0823434583.USD","BK4588","LU0289739699.SGD","BK4585","LU2106854487.HKD","LU2468319806.SGD","LU0882574055.USD","LU0823434740.USD","LU2023250504.SGD","LU1917777945.USD","LU2237438978.USD","LU1974910355.USD","LU2362541273.HKD","LU0114720955.EUR","LU0109394709.USD"],"gpt_icon":0},{"id":"2550966633","title":"Regeneron Pharma Is Maintained at Neutral by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2550966633","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550966633?lang=zh_cn&edition=full","pubTime":"2025-07-12 03:09","pubTimestamp":1752260940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/REGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 11, 2025 15:09 ET (19:09 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"瑞银维持再生元制药的评级为中性","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2550968645","title":"Regeneron Pharmaceuticals Launches Long-Term Follow-Up Study on Gene Modified T Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2550968645","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550968645?lang=zh_cn&edition=full","pubTime":"2025-07-12 00:27","pubTimestamp":1752251233,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals is initiating a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regeneron-pharmaceuticals-launches-long-term-follow-up-study-on-gene-modified-t-cell-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"再生元制药启动基因修饰T细胞疗法长期随访研究","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regeneron-pharmaceuticals-launches-long-term-follow-up-study-on-gene-modified-t-cell-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU2089984988.USD","LU0823416689.USD","REGN","LU0053666078.USD","LU0109394709.USD","LU2362541513.USD","LU2468319806.SGD","LU0889565916.HKD","LU0823434583.USD","LU0823434740.USD","LU2362540622.SGD","LU2106854487.HKD","LU2023250504.SGD","LU0320765992.SGD","LU0114720955.EUR","BK4585","LU1974910355.USD","LU2237438978.USD","LU0058720904.USD","LU0289739699.SGD","LU1917777945.USD","BK4588","LU0882574055.USD","LU2362541273.HKD"],"gpt_icon":0},{"id":"2550954563","title":"UBS Raises Price Target on Regeneron Pharmaceuticals to $584 From $560, Keeps Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2550954563","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550954563?lang=zh_cn&edition=full","pubTime":"2025-07-11 22:21","pubTimestamp":1752243712,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $726.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"瑞银将再生元制药目标价从560美元上调至584美元，维持中性评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN"],"gpt_icon":0},{"id":"2550799266","title":"US judge won't block 23andMe bankruptcy sale to co-founder","url":"https://stock-news.laohu8.com/highlight/detail?id=2550799266","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550799266?lang=zh_cn&edition=full","pubTime":"2025-07-11 05:22","pubTimestamp":1752182553,"startTime":"0","endTime":"0","summary":"US judge won't block 23andMe bankruptcy sale to co-founderBy Daniel Wiessner. July 10  - A federal judge on Thursday declined to block the bankruptcy sale of genetic testing company 23andMe to its co-founder Anne Wojcicki pending the outcome of a legal challenge by California.U.S. District Judge Matthew Schelp in St. Louis, Missouri, during a hearing said he would not pause the $305 million sale while he reviews the state's bid for a declaration that 23andMe cannot sell California customers' genetic data without their consent.    A bankruptcy judge rejected those claims on Monday, and California had appealed that ruling to Schelp, who on Tuesday had briefly paused the sale ahead of Thursday's hearing. 23andMe, which filed for bankruptcy in March, is selling its assets to TTAM Research, a new nonprofit founded by Wojcicki.On Thursday, Bernard Eskandari of the California Attorney General's office told Schelp that the state would have investigated and brought an enforcement action against","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"美国法官不会阻止23andMe破产出售给联合创始人","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nL1N3T40LH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4139","LU2106854487.HKD","LU2089984988.USD","LU2362541513.USD","LU0053666078.USD","LU2362541273.HKD","LU0289739699.SGD","LU0889565916.HKD","LU2023250504.SGD","LU0823434740.USD","REGN","LU0320765992.SGD","LU2362540622.SGD","LU0823434583.USD","LU2237438978.USD","BK4588","LU0114720955.EUR","BK4196","LU1974910355.USD","LU2468319806.SGD","LU1917777945.USD","BK4585","LU0823416689.USD","MEHCQ","LU0882574055.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2550414676","title":"Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2550414676","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550414676?lang=zh_cn&edition=full","pubTime":"2025-07-11 04:46","pubTimestamp":1752180360,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  rallied 1.30% to $559.76 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 0.27% to 6,280.46 and the Dow Jones Industrial Average  rising 0.43% to 44,650.64.This was the stock's third consecutive day of gains.Regeneron Pharmaceuticals Inc. closed 53.78% below its 52-week high of $1,211.20, which the company achieved on August 27th.The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Amgen Inc.  rose 1.30% to $300.37, Moderna Inc.  rose 4.54% to $34.28, and Gilead Sciences Inc.  rose 1.15% to $114.54.Trading volume  remained 563,143 below its 50-day average volume of 1.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled July 10, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is pu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"再生元制药公司股票在强劲交易日表现优于竞争对手","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2550462785","title":"Regeneron Pharma Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2550462785","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550462785?lang=zh_cn&edition=full","pubTime":"2025-07-11 00:23","pubTimestamp":1752164580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/REGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 10, 2025 12:23 ET (16:23 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"Regeneron Pharma由Morgan Stanley维持在跑赢大盘","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2550629919","title":"Refile- Regeneron Pharmaceuticals Inc. : Morgan Stanley Cuts Target Price to $754.00 From $755.00 (Fixes Company Name)","url":"https://stock-news.laohu8.com/highlight/detail?id=2550629919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550629919?lang=zh_cn&edition=full","pubTime":"2025-07-10 22:26","pubTimestamp":1752157577,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Refile-再生元制药公司：大摩将目标价从755.00美元下调至754.00美元（修正公司名称）","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nL4N3T717T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2237438978.USD","LU2362540622.SGD","LU0058720904.USD","LU2468319806.SGD","LU0823416689.USD","LU0289739699.SGD","LU2089984988.USD","LU0889565916.HKD","LU0823434583.USD","LU0109394709.USD","LU2362541273.HKD","LU0882574055.USD","LU1917777945.USD","BK4588","BK4139","LU2023250504.SGD","LU1974910355.USD","REGN","LU0823434740.USD","LU2106854487.HKD","LU0053666078.USD","LU0320765992.SGD","LU2362541513.USD","LU0114720955.EUR","BK4585"],"gpt_icon":0},{"id":"2550623778","title":"Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $754 From $755, Maintains Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2550623778","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550623778?lang=zh_cn&edition=full","pubTime":"2025-07-10 21:21","pubTimestamp":1752153661,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $726.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"大摩将再生元制药目标价从755美元调整至754美元，维持跑赢大盘评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN"],"gpt_icon":0},{"id":"2550628211","title":"Inc. : Morgan Stanley  Cuts Target Price to $754.00 From $755.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2550628211","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550628211?lang=zh_cn&edition=full","pubTime":"2025-07-10 20:52","pubTimestamp":1752151943,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Inc.：摩根士丹利将目标价从755.00美元下调至754.00美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nAZN45EBY2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0882574055.USD","LU2362541273.HKD","BK4585","LU2089984988.USD","LU0058720904.USD","LU1974910355.USD","LU2362541513.USD","LU2237438978.USD","BK4139","LU0889565916.HKD","LU0823434740.USD","LU2468319806.SGD","LU0114720955.EUR","LU0109394709.USD","LU0320765992.SGD","LU1917777945.USD","LU0823434583.USD","LU0289739699.SGD","BK4588","LU2106854487.HKD","LU0823416689.USD","LU2362540622.SGD","LU2023250504.SGD","LU0053666078.USD","REGN"],"gpt_icon":0},{"id":"2550692989","title":"再生元制药公司7月9日成交额为4.65亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550692989","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550692989?lang=zh_cn&edition=full","pubTime":"2025-07-10 13:22","pubTimestamp":1752124949,"startTime":"0","endTime":"0","summary":"美东时间2025年7月9日，再生元制药公司成交额为4.65亿美元，成交额较昨日减少0.25%，当日成交量为84.39万股。再生元制药公司于2025年7月9日涨0.88%，报552.58美元，该股过去5个交易日涨3.3%，年初至今跌22.21%，过去60日涨1.28%。该公司有多种已上市产品，包括获批用于湿性年龄相关性黄斑变性和其他眼病的低剂量Eylea 和 Eylea HD、免疫学领域的达必妥；用于降低低密度脂蛋白胆固醇的波立达；肿瘤学领域的Libtayo；以及类风湿性关节炎领域的Kevzara。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710132235a6a0d2b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2237438978.USD","LU2362540622.SGD","LU0058720904.USD","LU2468319806.SGD","LU0823416689.USD","LU0289739699.SGD","LU2089984988.USD","LU0889565916.HKD","LU0823434583.USD","LU0109394709.USD","LU2362541273.HKD","LU0882574055.USD","LU1917777945.USD","BK4588","BK4139","LU2023250504.SGD","LU1974910355.USD","REGN","LU0823434740.USD","LU2106854487.HKD","LU0053666078.USD","LU0320765992.SGD","LU2362541513.USD","LU0114720955.EUR","BK4585"],"gpt_icon":0},{"id":"2550317658","title":"Maia Biotechnology Inc. Expands Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer with First Patient Dosed in Taiwan","url":"https://stock-news.laohu8.com/highlight/detail?id=2550317658","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550317658?lang=zh_cn&edition=full","pubTime":"2025-07-09 21:15","pubTimestamp":1752066924,"startTime":"0","endTime":"0","summary":"Maia Biotechnology Inc. Expands Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer with First Patient Dosed in Taiwan. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via Business Wire  on July 09, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Maia Biotechnology Inc.扩大Ateganosine治疗晚期非小细胞肺癌的2期试验，台湾首例患者接受给药","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nNDL5SDGD1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362540622.SGD","LU2362541273.HKD","BK4588","LU1917777945.USD","BK4585","LU0320765992.SGD","LU2023250504.SGD","MAIA","LU0823434740.USD","LU2468319806.SGD","LU0058720904.USD","BK4139","LU2362541513.USD","LU0823434583.USD","LU0114720955.EUR","LU0882574055.USD","LU0889565916.HKD","LU2089984988.USD","LU2237438978.USD","LU0053666078.USD","LU2106854487.HKD","LU0289739699.SGD","LU1974910355.USD","REGN","LU0823416689.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2550507822","title":"再生元制药公司7月8日成交额为4.66亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550507822","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550507822?lang=zh_cn&edition=full","pubTime":"2025-07-09 13:22","pubTimestamp":1752038547,"startTime":"0","endTime":"0","summary":"美东时间2025年7月8日，再生元制药公司成交额为4.66亿美元，成交额较昨日减少9.67%，当日成交量为84.74万股。再生元制药公司于2025年7月8日涨1.79%，报547.75美元，该股过去5个交易日涨4.33%，年初至今跌22.89%，过去60日跌4.88%。该公司有多种已上市产品，包括获批用于湿性年龄相关性黄斑变性和其他眼病的低剂量Eylea 和 Eylea HD、免疫学领域的达必妥；用于降低低密度脂蛋白胆固醇的波立达；肿瘤学领域的Libtayo；以及类风湿性关节炎领域的Kevzara。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709132236a43f8676&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LU1974910355.USD","LU0053666078.USD","LU0823434740.USD","LU0289739699.SGD","LU0823416689.USD","LU2362541273.HKD","LU1917777945.USD","LU0882574055.USD","LU2089984988.USD","LU0823434583.USD","LU2362540622.SGD","REGN","LU2237438978.USD","BK4588","LU0114720955.EUR","LU0889565916.HKD","LU2468319806.SGD","BK4139","LU0109394709.USD","LU2023250504.SGD","LU2362541513.USD","LU2106854487.HKD","LU0320765992.SGD","LU0058720904.USD"],"gpt_icon":0},{"id":"2550207645","title":"Regeneron's Blockbuster Dupixent Faces a New Rival -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2550207645","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550207645?lang=zh_cn&edition=full","pubTime":"2025-07-09 03:31","pubTimestamp":1752003060,"startTime":"0","endTime":"0","summary":"With $17 billion in annual sales, Dupixent is a franchise drug for its 50/50 owners Sanofi and Regeneron Pharmaceuticals. So rivals have lined up to challenge the antibody treatment against autoimmune disorders such as dermatitis and asthma.Monday, Apogee Therapeutics reported quite competitive results among dermatitis patients in its Phase 2 trial of a drug that might require fewer injections than Dupixent. Guggenheim Securities analyst Seamus Fernandez said the drug is on track to be a best-in-class treatment and reaffirmed Apogee as his best investment idea.Others disagreed. Apogee stock sank 17% in heavy trading, to end Monday at $39. Tuesday morning, it slipped another couple of bucks, while Regeneron rose 3%, to $556.Apogee's APG777 antibody sops up IL-13, an immune system molecule that causes much of the itchy scaling of dermatitis. Over 16 weeks of the study, 42% of patients saw improvement on 75% of the skin area affected by eczema, compared with a placebo. Lilly's drug delive","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"再生元的重磅炸弹Dupixent面临新竞争对手——Barrons.com","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1291159041.SGD","BK4581","IE00BFTCPJ56.SGD","LU0053666078.USD","LU2237443382.USD","LU2357305700.SGD","LU0417517546.SGD","LU1064131342.USD","IE00BJLML261.HKD","SG9999014898.SGD","LU1868836914.USD","REGN","LU0122379950.USD","SNY","LU2552382132.HKD","APGE","IE0009355771.USD","LU0106261372.USD","LU2750360997.AUD","LU0323591593.USD","SG9999015978.USD","LU2089984988.USD","LU0466842654.USD","LU2265009873.SGD","LU2750360641.GBP","IE0002141913.USD","LU1868837300.USD","LU0256863811.USD","SG9999014906.USD","LU1093756325.SGD","BK4139","BK4534","LU0096364046.USD","LU1720051017.SGD","IE00B2B36J28.USD","LU2324357040.USD","LU2456880835.USD","LU2237443978.SGD","LU1366192091.USD","LU0471298694.HKD","LU2112291526.USD","LU2237443622.USD","LU0689472784.USD","SG9999015952.SGD","GB00BDT5M118.USD","LU2023250504.SGD","SGXZ57979304.SGD","LU2237438978.USD","LU0234572021.USD"],"gpt_icon":1},{"id":"2549559256","title":"Analysts Are Bullish on These Healthcare Stocks: Sanofi (SNYNF), Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2549559256","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549559256?lang=zh_cn&edition=full","pubTime":"2025-07-08 13:50","pubTimestamp":1751953829,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sanofi (SNYNF – Research Report) and Regeneron (REGN...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-sanofi-snynf-regeneron-regn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"分析师看好这些医疗保健股：赛诺菲(SNYNF)、再生元(REGN)","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-sanofi-snynf-regeneron-regn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2089984988.USD","BK4137","LU2468319806.SGD","LU0053666078.USD","LU1974910355.USD","LU2106854487.HKD","LU2362540622.SGD","HCSG","LU0823416689.USD","LU2362541273.HKD","SNYNF","LU0114720955.EUR","LU0320765992.SGD","LU0823434583.USD","BK4585","LU0289739699.SGD","LU0889565916.HKD","LU1917777945.USD","REGN","BK4007","LU0823434740.USD","LU2362541513.USD","BK4139","LU2023250504.SGD","LU0882574055.USD","LU2237438978.USD","BK4588","LU0058720904.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2549570594","title":"再生元制药公司7月7日成交额为5.16亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549570594","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549570594?lang=zh_cn&edition=full","pubTime":"2025-07-08 13:14","pubTimestamp":1751951687,"startTime":"0","endTime":"0","summary":"美东时间2025年7月7日，再生元制药公司成交额为5.16亿美元，成交额较昨日增加106.35%，当日成交量为96.03万股。再生元制药公司于2025年7月7日跌1.69%，报538.11美元，该股过去5个交易日涨3.28%，年初至今跌24.25%，过去60日跌3.21%。该公司有多种已上市产品，包括获批用于湿性年龄相关性黄斑变性和其他眼病的低剂量Eylea 和 Eylea HD、免疫学领域的达必妥；用于降低低密度脂蛋白胆固醇的波立达；肿瘤学领域的Libtayo；以及类风湿性关节炎领域的Kevzara。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708131458a69c5e7d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2023250504.SGD","LU0058720904.USD","LU0823416689.USD","LU1917777945.USD","LU0882574055.USD","LU2237438978.USD","LU2362541513.USD","LU2362541273.HKD","REGN","LU0109394709.USD","LU2362540622.SGD","LU0889565916.HKD","LU0320765992.SGD","LU0823434740.USD","BK4585","LU2468319806.SGD","LU0053666078.USD","LU0114720955.EUR","LU2089984988.USD","BK4588","LU0289739699.SGD","LU0823434583.USD","LU2106854487.HKD","BK4139","LU1974910355.USD"],"gpt_icon":0},{"id":"2549568729","title":"加州未能阻止 23andMe 创始人重新收购公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2549568729","media":"路透中文","labels":["shareholding","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549568729?lang=zh_cn&edition=full","pubTime":"2025-07-08 05:36","pubTimestamp":1751924168,"startTime":"0","endTime":"0","summary":"23andMe 于今年 3 月申请破产 ，在消费者需求下降 ，以及 2023 年数据泄露 ，数百万客户的基因数据曝光后，该公司寻求出售其业务。该州曾试图阻止加州客户的数据被转移，23andMe 称这一步骤将有效扼杀销售。根据加州的法庭文件，在 23andMe 库存的约 1000 万份基因档案中，加州消费者约占 180 万。TTAM Research在今年6月的23andMe资产破产拍卖中胜出，超过了Regeneron Pharmaceuticals REGN.O公司2.65亿美元的出价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nL4T3T418E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU0823434583.USD","MEHCQ","BK4585","LU0114720955.EUR","LU2362540622.SGD","REGN","BK4588","BK4196","LU1917777945.USD","LU0109394709.USD","LU0889565916.HKD","LU2237438978.USD","LU0289739699.SGD","LU0320765992.SGD","LU2362541273.HKD","LU0823416689.USD","BK4139","LU0823434740.USD","LU1974910355.USD","LU0058720904.USD","LU0053666078.USD","LU2106854487.HKD","LU2362541513.USD","LU2468319806.SGD","LU2089984988.USD","LU2023250504.SGD"],"gpt_icon":0},{"id":"2549568725","title":"California fails to stop 23andMe founder from re-acquiring company","url":"https://stock-news.laohu8.com/highlight/detail?id=2549568725","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549568725?lang=zh_cn&edition=full","pubTime":"2025-07-08 05:35","pubTimestamp":1751924159,"startTime":"0","endTime":"0","summary":"California fails to stop 23andMe founder from re-acquiring companyBy Dietrich Knauth","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"加州未能阻止23andMe创始人重新收购公司","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nL6N3SN0OT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0823434740.USD","LU2468319806.SGD","BK4139","LU0058720904.USD","REGN","LU2237438978.USD","LU0053666078.USD","LU0109394709.USD","LU2362541273.HKD","LU1917777945.USD","MEHCQ","LU2362540622.SGD","LU0114720955.EUR","LU0823434583.USD","LU0882574055.USD","LU2089984988.USD","LU2106854487.HKD","LU0889565916.HKD","BK4196","BK4588","LU0289739699.SGD","LU1974910355.USD","LU2023250504.SGD","LU2362541513.USD","LU0320765992.SGD","BK4585"],"gpt_icon":0},{"id":"2549550050","title":"Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2549550050","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549550050?lang=zh_cn&edition=full","pubTime":"2025-07-08 04:47","pubTimestamp":1751921220,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  shed 1.69% to $538.11 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index  falling 0.79% to 6,229.98 and Dow Jones Industrial Average  falling 0.94% to 44,406.36.This was the stock's second consecutive day of losses.Regeneron Pharmaceuticals Inc. closed 55.57% below its 52-week high of $1,211.20, which the company achieved on August 27th.The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Amgen Inc.  fell 1.77% to $292.95, Moderna Inc.  fell 1.94% to $29.90, and Gilead Sciences Inc.  rose 0.03% to $111.78.Trading volume  remained 445,048 below its 50-day average volume of 1.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled July 7, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published i","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"尽管当天下跌，再生元制药公司股票的表现仍优于竞争对手","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":0.0372},{"period":"1month","weight":0.0948},{"period":"3month","weight":0.0245},{"period":"6month","weight":-0.1853},{"period":"1year","weight":-0.4744},{"period":"ytd","weight":-0.203}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.037},{"period":"3month","weight":0.168},{"period":"6month","weight":0.0743},{"period":"1year","weight":0.1207},{"period":"ytd","weight":0.0641}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州成立。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。其正在开发的商业化药物和候选产品旨在帮助患有眼疾、过敏性和炎症性疾病、癌症、心血管和代谢性疾病、疼痛、传染病和罕见疾病的患者。它的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类疾病的重要选择。","yearOnYearQuotes":[{"month":1,"riseRate":0.529412,"avgChangeRate":0.03899},{"month":2,"riseRate":0.411765,"avgChangeRate":0.087815},{"month":3,"riseRate":0.470588,"avgChangeRate":-0.044318},{"month":4,"riseRate":0.470588,"avgChangeRate":0.017191},{"month":5,"riseRate":0.628571,"avgChangeRate":0.057479},{"month":6,"riseRate":0.428571,"avgChangeRate":0.006745},{"month":7,"riseRate":0.657143,"avgChangeRate":0.053858},{"month":8,"riseRate":0.529412,"avgChangeRate":0.02165},{"month":9,"riseRate":0.470588,"avgChangeRate":0.0249},{"month":10,"riseRate":0.382353,"avgChangeRate":-0.006135},{"month":11,"riseRate":0.529412,"avgChangeRate":0.041578},{"month":12,"riseRate":0.5,"avgChangeRate":0.045405}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况